- Home
- SNTG vs REVB Comparison
SNTG vs REVB Comparison
Compare SNTG & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNTG | REVB |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNTG | REVB |
|---|---|---|
| Price | $2.32 | $0.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.8K | ★ 105.9K |
| Earning Date | 04-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,507.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $0.83 |
| 52 Week High | $12.70 | $60.48 |
Technical Indicators
Market Signals| Indicator | SNTG | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 37.17 |
| Support Level | $2.17 | $0.93 |
| Resistance Level | $2.65 | $1.20 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 34.57 | 6.82 |
Price Performance
Historical ComparisonAbout SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).